tiprankstipranks
Trending News
More News >
Regeneron (REGN)
NASDAQ:REGN
US Market
Advertisement

Regeneron (REGN) Earnings Dates, Call Summary & Reports

Compare
4,858 Followers

Earnings Data

Report Date
Oct 30, 2025
Before Open (Confirmed)
Period Ending
2025 (Q3)
Consensus EPS Forecast
9.67
Last Year’s EPS
12.46
Same Quarter Last Year
Moderate Buy
Based on 25 Analysts Ratings

Earnings Call Summary

Q2 2025
Earnings Call Date:Aug 07, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
Regeneron showed strong performance in key products like Dupixent and Libtayo, successful launches, and robust financial results, offsetting the declines in EYLEA sales and regulatory delays. The company's significant R&D investments indicate a focus on future growth, despite facing competitive pressures and market dynamics.
Company Guidance
During Regeneron's Q2 2025 earnings call, the company provided several key financial metrics and guidance updates. Dupixent's global net product sales increased by 21% to $4.3 billion, and Libtayo's sales grew by 25% on a constant currency basis. EYLEA HD in the U.S. saw a significant 29% growth compared to the same quarter last year, with net product sales reaching $393 million. However, EYLEA's U.S. net product sales were $754 million, marking a 39% decline year-over-year. The company anticipates continued challenges for EYLEA due to competitive pressures and pricing issues. Regeneron updated its 2025 financial guidance, noting a combined net decrease of $125 million at the midpoints for SG&A, R&D, and cost of goods sold expenses. The company expects its effective tax rate to trend towards the mid-teens over time. Additional pipeline updates and strategic capital allocation plans were discussed, emphasizing ongoing investments in research and development and manufacturing capabilities, with over $7 billion earmarked for expansion in the U.S.
Strong Growth in Key Products
Dupixent global net product sales increased by 21% to $4.3 billion, and Libtayo sales grew by 25% to $377 million on a constant currency basis compared to the previous year.
Successful Launches and Pipeline Advances
Lynozyfic was FDA approved for relapsed/refractory multiple myeloma, and several new indications for Dupixent were approved, potentially treating over 600,000 additional patients.
Robust Financial Performance
Second quarter diluted net income per share grew 12% to $12.89, and the company generated $1.7 billion in free cash flow for the first half of 2025.
Significant R&D Investments
Investments over $7 billion in the U.S. for expanding R&D and manufacturing capabilities, with a strong pipeline of approximately 45 product candidates.

Regeneron (REGN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

REGN Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Oct 30, 2025
2025 (Q3)
9.67 / -
12.46
Aug 07, 2025
2025 (Q2)
8.43 / 12.89
11.5611.51% (+1.33)
Apr 29, 2025
2025 (Q1)
8.62 / 8.22
9.55-13.93% (-1.33)
Feb 04, 2025
2024 (Q4)
11.28 / 12.07
11.861.77% (+0.21)
Oct 31, 2024
2024 (Q3)
11.70 / 12.46
11.597.51% (+0.87)
Aug 01, 2024
2024 (Q2)
10.62 / 11.56
10.2412.89% (+1.32)
May 02, 2024
2024 (Q1)
10.17 / 9.55
10.09-5.35% (-0.54)
Feb 02, 2024
2023 (Q4)
10.73 / 11.86
12.56-5.57% (-0.70)
Nov 02, 2023
2023 (Q3)
10.68 / 11.59
11.144.04% (+0.45)
Aug 03, 2023
2023 (Q2)
9.85 / 10.24
9.774.81% (+0.47)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

REGN Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Aug 07, 2025
$554.29$558.95+0.84%
Apr 29, 2025
$609.03$567.21-6.87%
Feb 04, 2025
$664.00$694.07+4.53%
Oct 31, 2024
$918.85$834.62-9.17%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Regeneron (REGN) report earnings?
Regeneron (REGN) is schdueled to report earning on Oct 30, 2025, Before Open (Confirmed).
    What is Regeneron (REGN) earnings time?
    Regeneron (REGN) earnings time is at Oct 30, 2025, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is REGN EPS forecast?
          REGN EPS forecast for the fiscal quarter 2025 (Q3) is 9.67.

            Regeneron (REGN) Earnings News

            Regeneron (NASDAQ:REGN) Jumps on Q4 Beat
            Premium
            Market News
            Regeneron (NASDAQ:REGN) Jumps on Q4 Beat
            2y ago
            Regeneron Posts Q4 Beat; Shares Rise
            Premium
            Market News
            Regeneron Posts Q4 Beat; Shares Rise
            3y ago
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis